原发性难治/复发性继发性与原发性急性髓系白血病的单倍体移植:来自ALWP/EBMT的报告
比较了2010至2022年间接受移植后环磷酰胺单倍体造血干细胞移植的719例原发难治或首次复发继发性急性髓系白血病(n=129)与原发急性髓系白血病(n=590)患者的结局。继发性急性髓系白血病组原发难治比例更高(73.6% vs 58.6%;P=.002)。多变量分析显示两组移植结局无显著差异。
要点
- 继发性急性髓系白血病组原发难治比例高于原发急性髓系白血病组(73.6% vs 58.6%;P=.002)。
- 多变量分析中两组非复发死亡HR 1.38(95%CI 0.96-1.98;P=.083),无显著差异。
- 无白血病生存、总生存及无GVHD无复发生存的HR均为0.99,组间无显著差异。
核心结论
- 接受移植后环磷酰胺单倍体造血干细胞移植的原发难治/复发继发性急性髓系白血病与原发难治/复发原发急性髓系白血病患者结局无显著差异,作者认为这一发现具有重要临床意义。
研究设计与样本
- 比较2010年至2022年间接受移植后环磷酰胺单倍体造血干细胞移植的原发难治或首次复发继发性急性髓系白血病患者(n=129)与原发急性髓系白血病患者(n=590)的结局,共719例。
主要发现
- 继发性急性髓系白血病组原发难治比例为73.6%,原发急性髓系白血病组为58.6%(P=.002)。
- 继发性急性髓系白血病组81.4%的患者 antecedent hematological disorder 为骨髓增生异常综合征。
- 植入率在继发性急性髓系白血病组为83.5%,原发急性髓系白血病组为88.4%(P=.13)。
- 多变量分析中非复发死亡HR为1.38(95%CI 0.96-1.98;P=.083),复发发生率HR为0.68(95%CI 0.4.7.-1.00;P=.051),原文置信区间写作0.4.7.,表述有误。
- 无白血病生存、总生存、无GVHD及无GVHD无复发生存的HR分别为0.99(95%CI 0.76-1.28;P=.94)、0.99(95%CI 0.77-1.29;P=.97)和0.99(95%CI 0.77-1.27;P=.94)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We compared the outcomes of haploidentical stem cell transplantation (haplo-HSCT) with posttransplant cyclophosphamide (PTCy) in 719 patients with primary refractory (PR) or first relapse (Rel) secondary acute myeloid leukemia (sAML; n = 129) vs those with de novo AML (n = 590), who received HSCT between 2010 and 2022. A higher percentage of patients with sAML vs de novo AML had PR disease (73.6% vs 58.6%; P = .002). In 81.4% of patients with sAML , the antecedent hematological disorder was myelodysplastic syndrome. Engraftment was 83.5% vs 88.4% in sAML and de novo AML, respectively (P = .13). In multivariate analysis, haplo-HSCT outcomes did not differ significantly between the groups: nonrelapse mortality hazard ratio (HR), 1.38 (95% confidence interval [CI], 0.96-1.98; P = .083), relapse incidence HR, 0.68 (95% CI, 0.4.7.-1.00; P = .051). The HRs for leukemia-free survival, overall survival, and graft-versus-host disease (GVHD)-free, and GVHD and relapse-free survival were 0.99 (95% CI, 0.76-1.28; P = .94), 0.99 (95% CI, 0.77-1.29; P = .97), and 0.99 (95% CI, 0.77-1.27; P = .94), respectively. We conclude that outcomes of haplo-HSCT with PTCy are not different for PR/Rel sAML in comparison with PR/Rel de novo AML, a finding of major clinical importance.
引用
- Nagler A, Labopin M, Tischer J, et al. Haploidentical transplantation in primary refractory/relapsed secondary vs de novo AML: from the ALWP/EBMT. Blood Adv. 2024. PMID: 38598754. doi:10.1182/bloodadvances.2024012798
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。